Axonics Modulation Technologies (AXNX) Financials

Axonics Modulation Technologies Inc (AXNX) is a medical technology company that specializes in the development and commercialization of innovative neuromodulation technologies. The company's primary product is the Axonics r-SNM System, which is a rechargeable implantable neuromodulation system used for the treatment of overactive bladder (OAB) and urinary retention. The Axonics r-SNM System is the first and only rechargeable sacral neuromodulation system approved for sale in the United States, Europe, Canada, and Australia.

In terms of financial performance, Axonics Modulation Technologies Inc has demonstrated strong growth and profitability. According to the company's income statement, Axonics Modulation Technologies Inc generated total revenue of $49.9 million in the most recent fiscal year. This represents a significant increase compared to the previous year's revenue of $19 million. The company's gross profit for the most recent fiscal year was $34.8 million, with a gross margin of 69.8%.

Axonics Modulation Technologies Inc also reported a positive net income from stockholders in the most recent fiscal year. The net income was $10.5 million, which is a substantial improvement compared to the previous year's net loss of $7.3 million. This improvement can be attributed to the company's strong sales growth and improved operational efficiency.

In terms of financial position, Axonics Modulation Technologies Inc has a strong balance sheet. The company's total assets amount to $217 million, with total liabilities of $69.7 million. This results in a stockholders' equity of $147.3 million, indicating a healthy financial position.

Axonics Modulation Technologies Inc also has a solid cash flow. The operating cash flow for the most recent fiscal year was $3.5 million, indicating positive cash generation from the company's core operations. The investing cash flow was -$1.6 million, primarily due to investments in property and equipment. The financing cash flow was $2.2 million, representing cash inflows from financing activities such as equity offerings.

Overall, Axonics Modulation Technologies Inc has exhibited strong financial performance and a solid financial position. The company's revenue and gross profit have experienced significant growth, while net income has improved from a loss to a positive figure. With a strong balance sheet and positive cash flow, Axonics Modulation Technologies Inc is well-positioned for continued success in the medical technology industry.